For a small number of companies in the biomedical field who were pursuing this approach it means their research into gene therapies will probably take a different tack or they will be out of business. My guess is biomedical research interested in patents will look at synthetic DNA and creating delivery mechanisms for providing genetic material to effect cures.
But better yet, this ruling should open up the application of genetic research in a much wider manner bringing in the collective wisdom of numerous universities, medical research centres and hospitals who are actively pursuing DNA-based therapies to deal with many diseases including cancer.
]]>